Abstract: The present invention relates to novel benzimidazolone derivatives of the general formula (I) in which the substituents R1, R2, R3, A1, A2, and B are as defined in claim 1, medicaments comprising these, and the use thereof for the prophylaxis and/or treatment of vasopressin-dependent diseases.
Abstract: A pharmaceutical dosage form comprises a solid dispersion product of at least one active ingredient dispersed in a polymeric binder composition, the polymeric carrier composition comprising a) a vinylpyrrolidone homopolymer, wherein at least 95% by weight of the vinylpyrrolidone homopolymer has a molecular weight distribution within the range of from 1000 to 13 000; and b) a vinylpyrrolidone copolymer having a weight-average molecular weight of from 5000 to 1 500 000. The dosage form is preferably prepared by a melt extrusion process. The polymeric carrier composition exhibits a high drug dissolution power and allows a reduction of the viscosity of the melt without deteriorating the mechanical properties and storage stability of the dosage form.
Type:
Application
Filed:
January 10, 2014
Publication date:
July 17, 2014
Applicant:
Abbvie Deutschland GmbH & Co. KG
Inventors:
Bernd Liepold, Jörg Breitenbach, Markus Mägerlein, Claudia Henzel, Thomas K. Kessler
Abstract: The present invention relates to benzenesulfonyl or sulfonamide compounds of formulae IA and IB wherein the variables have the meanings given in the claims and the description, pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties and are particularly suitable for treating diseases that respond to modulation of the serotonin 5-HT6 receptor.
Type:
Grant
Filed:
November 1, 2011
Date of Patent:
July 8, 2014
Assignees:
Abbott Laboratories, AbbVie Deutschland GmbH & Co. KG
Inventors:
Andreas Haupt, Frauke Pohlki, Liliane Unger, Ana Lucia Relo, Karsten Wicke, Min Zhang
Abstract: The present invention relates to N-Phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds of formula I wherein the variables have the meanings given in the claims and the description, pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties and are particularly suitable for treating diseases that respond to modulation of the serotonin 5-HT6 receptor.
Type:
Grant
Filed:
November 1, 2011
Date of Patent:
April 29, 2014
Assignees:
Abbott Laboratories, AbbVie Deutschland GmbH & Co. KG
Inventors:
Andreas Haupt, Frauke Pohlki, Liliane Unger, Ana Lucia Relo, Karsten Wicke, Min Zhang
Abstract: The present invention relates to novel amidomethyl-substituted oxindole derivatives, pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-dependent disorders.
Type:
Grant
Filed:
December 5, 2008
Date of Patent:
April 22, 2014
Assignee:
AbbVie Deutschland GmbH & Co. KG
Inventors:
Thorsten Oost, Astrid Netz, Herve Geneste, Wilfried Braje, Liliane Unger, Wilfried Hornberger, Wilfried Lubisch, Andrea Hager-Wernet
Abstract: The present invention relates to novel carbamate-substituted oxindole derivatives, pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-dependent disorders.
Type:
Grant
Filed:
December 5, 2008
Date of Patent:
April 22, 2014
Assignee:
AbbVie Deutschland GmbH & Co. KG
Inventors:
Astrid Netz, Thorsten Oost, Herve Geneste, Wilfried Braje, Liliane Unger, Wilfried Hornberger, Wilfried Lubisch, Andrea Hager-Wernet
Abstract: Anti-A? globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies. The present invention relates to anti-A? globulomer antibodies having a binding affinity to A?(20-42) globulomer that is greater than the binding affinity of the antibody to A?(1-42) globulomer, antigen-binding moieties thereof, hybridomas producing said antibodies, nucleic acids encoding said antibodies, vectors comprising said nucleic acids, host cells comprising said vectors, methods of producing said antibodies, compositions comprising said antibodies, therapeutic and diagnostic uses of said antibodies and corresponding methods relating to Alzheimer's disease and other amyloidoses.
Type:
Grant
Filed:
November 30, 2006
Date of Patent:
April 8, 2014
Assignees:
AbbVie Inc., AbbVie Deutschland GmbH & Co. KG
Inventors:
Stefan Barghorn, Heinz Hillen, Boris Labkovsky, Andreas R. Striebinger, Patrick Keller, Ulrich Ebert
Abstract: The invention relates to novel oxindol derivative of general formula (I), wherein substituents R1, R2, A, B and Y are such as defined in a claim 1. Drugs containing said derivatives and the use thereof for preventing and/or treating vassopress-and/or oxytocin-dependent-diseases are also disclosed.
Abstract: A process for producing a solid dispersion of an active ingredient which comprises feeding the active ingredient and a matrix-forming agent to an extruder and forming a uniform extrudate, wherein the extruder comprises at least two rotating shafts (2), each of the shafts (2) carrying a plurality of processing elements disposed axially one behind the other, the processing elements defining (i) a feeding and conveying section (A), (ii) at least one mixing section (B), and (iii) a discharging section (E), wherein the processing element(s) defining the mixing section (B) comprise(s) a mixing element (11, 12, 13) that is derived from a screw type element (FIG. 2).
Type:
Application
Filed:
December 2, 2013
Publication date:
April 3, 2014
Applicant:
AbbVie Deutschland GmbH & Co. KG
Inventors:
Thomas Kessler, Jörg Breitenbach, Christoph Schmidt, Matthias Degenhardt, Jörg Rosenberg, Harald Krull
Abstract: The invention relates to compounds of general formula (I), corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof and the prodrugs of said compounds. The invention also relates to the use of said compounds as binding partners for 5-HT5 receptors for treating diseases that are modulated by a 5-HT5 receptor activity, in particular, for treating neurodegenerative and neuropsychiatric disorders as well as signs, symptoms and dysfunctions.
Type:
Grant
Filed:
August 21, 2006
Date of Patent:
April 1, 2014
Assignee:
AbbVie Deutschland GmbH & Co. KG
Inventors:
Wilhelm Amberg, Astrid Netz, Andreas Kling, Michael Ochse, Udo Lange, Charles W. Hutchins, Francisco Javier Garcia-Ladona, Alfred Hahn
Abstract: A process for producing a solid dispersion of an active ingredient which comprises feeding the active ingredient and a matrix-forming agent to an extruder and forming a uniform extrudate, wherein the extruder comprises at least two rotating shafts (2), each of the shafts (2) carrying a plurality of processing elements disposed axially one behind the other, the processing elements defining (i) a feeding and conveying section (R; A), (ii) at least one reverse-flight section (D), and (iii) a discharging section (E), wherein the processing elements defining the reverse-flight section (R; D) comprise at least one reverse-flight element (14) which is based on a screw-type element having a conveying direction being opposite to the general conveying direction of the extruder.
Type:
Application
Filed:
December 2, 2013
Publication date:
March 27, 2014
Applicant:
AbbVie Deutschland GmbH & Co. KG
Inventors:
Thomas Kessler, Jörg Breitenbach, Christoph Schmidt, Matthias Degenhardt, Jörg Rosenberg, Harald Krull, Gunther Berndl
Abstract: The present invention relates to a solid dosage form with at least one film, which contains an active substance at least in sections, and the concentration of the active substance in the film or in the films has a gradient in a direction normal to the thickness of film. The invention further relates to a method of producing a solid dosage form, in which at least one film is produced, containing an active substance at least in sections, with the concentration of the active substance having a gradient in the longitudinal direction of the film.
Type:
Grant
Filed:
November 12, 2007
Date of Patent:
March 18, 2014
Assignee:
Abbvie Deutschland GmbH & Co. KG
Inventors:
Jörg Rosenberg, Jörg Breitenbach, Peter Heilmann, Helmuth Steininger
Abstract: The present invention relates to small molecule potentiators of metabotropic receptors, in particular of the mGlu2 receptor. The present invention also relates to the use of these compounds for the prevention or treatment of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The present invention thus provides compounds of formula I and variables defined herein.
Type:
Grant
Filed:
March 25, 2011
Date of Patent:
March 4, 2014
Assignee:
AbbVie Deutschland GmbH & Co. KG
Inventors:
Wilfried Braje, Katja Jantos, Hervé Geneste, Mario Mezler, Margaretha Henrica Maria Bakker, Jayne Froggett
Abstract: The present invention relates to tetrahydroisoquinoline of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such tetrahydroisoquinolines, and the use of such tetrahydroisoquinolines for therapeutic purposes. The tetrahydroisoquinolines are GlyT1 inhibitors.
Type:
Grant
Filed:
March 31, 2009
Date of Patent:
February 18, 2014
Assignees:
AbbVie Inc., AbbVie Deutschland GmbH & Co. KG
Inventors:
Michael Ochse, Udo Lange, Wilfried Braje, Berthold Behl, Wilfried Hornberger, Mario Mezler, Wilhelm Amberg, Charles W. Hutchins
Abstract: The present invention relates to heterocyclic compounds of the formula (I) or a physiologically tolerated salt thereof. The present invention also relates to pharmaceutical compositions comprising such heterocyclic compounds, and the use of such heterocyclic compounds for therapeutic purposes.
Type:
Grant
Filed:
February 16, 2010
Date of Patent:
February 4, 2014
Assignee:
AbbVie Deutschland GmbH & Co. KG
Inventors:
Udo Lange, Andreas Heutling, Wilhelm Amberg, Michael Ochse, Berthold Behl, Wilfried Hornberger, Mario Mezler
Abstract: The invention relates to compounds of the formula (I) wherein the variables have meanings given in the claims and the description. The invention also relates to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof for preparing a medicament for the treatment of a medical disorder susceptible to the treatment with a 5HT6 receptor ligand.
Type:
Grant
Filed:
April 18, 2007
Date of Patent:
February 4, 2014
Assignees:
Abbott Laboratories, AbbVie Deutschland GmbH & Co. KG
Inventors:
Roland Grandel, Wilfried Martin Braje, Andreas Haupt, Sean Colm Turner, Udo Lange, Karla Drescher, Liliane Unger, Dan Plata
Abstract: The present invention relates to a heterocyclic compound of the general formula (I) and their use and preparation, methods of making the compounds, compositions containing at least one of said compounds, and methods of treatment using at least one compound. In particular, compounds of the general formula (I) are useful for inhibiting glycogen synthase kinase 3 (GSK-3).
Type:
Grant
Filed:
October 19, 2007
Date of Patent:
February 4, 2014
Assignees:
AbbVie Inc., AbbVie Deutschland GmbH & Co. KG
Inventors:
Sean C. Turner, Margaretha Henrica Maria Bakker, Kent D. Stewart
Abstract: The present invention relates to novel substituted oxindole derivatives of the formula (I), pharmaceutical agents containing said derivatives, and the use thereof for the treatment of vasopressin-dependent illnesses.
Type:
Grant
Filed:
December 23, 2008
Date of Patent:
January 14, 2014
Assignee:
AbbVie Deutschland GmbH & Co. KG
Inventors:
Wilfried Braje, Astrid Netz, Thorsten Oost, Liliane Unger, Wilfried Hornberger, Wilfried Lubisch, Andrea Hager-Wernet
Abstract: A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ETA) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ETA receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ETA receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ETA receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETA receptor antagonist.
Type:
Grant
Filed:
February 13, 2013
Date of Patent:
January 7, 2014
Assignee:
AbbVie Deutschland GmbH & Co. KG
Inventors:
Robert L. Roden, Richard J. Gorczynski, Michael J. Gerber